Clinical Data ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis Pharmaceutical Technology48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.RespiratoryRead full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology 48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Remepy’s hybrid Parkinson’s therapy poised for phase 3Next: ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
